Find Academic Supervisors

• Genetics
• Genomics
• DNA Sequence Analysis
• +2 more

Dr. Shrikant Mane is a Professor of Genetics at Yale School of Medicine, where he directs the Yale Center for Genome Analysis (YCGA) Shared Resource and The Keck Biotechnology Resource Laboratory. He has over 25 years of research experience in both academic and private industry settings, with expertise in genomic and proteomic analyses using microarray and high-throughput DNA sequencing technologies. Dr. Mane received his Ph.D. in Cancer Biology in 1985 and completed his postdoctoral training at Johns Hopkins University School of Medicine. He has published over 125 scientific articles and holds 2 patents. His research spans genetics, genomics, DNA sequence analysis, neuroscience, and cancer biology, with a particular focus on Mendelian genomics and disease gene discovery. His laboratory work has provided over 58,000 sequence analyses to 225 Yale and 124 non-Yale principal investigators from 72 national and 16 international institutions. Dr. Mane is one of four Principal Investigators of the Yale Center for Mendelian Genomics, established in 2012 through an $11.2 million grant from NHGRI. His recent publications (2023-2025) demonstrate a strong focus on identifying genetic causes of kidney disorders, congenital heart disease, and neurodevelopmental conditions through large-scale genomic studies published in high-impact journals including Nature, Nature Communications, and PNAS. Notable Achievements: Principal Investigator of the Yale Center for Mendelian Genomics ($11.2 million NHGRI grant) Director of Yale Center for Genome Analysis serving hundreds of researchers worldwide Published over 125 scientific articles in genetics and genomics Extensive experience with genomic technologies spanning 25+ years Dr. Mane's laboratory serves as a major resource for genomic analysis at Yale and beyond, supporting numerous research projects through cutting-edge sequencing and analysis capabilities. His research program bridges technological development with clinical applications, particularly in the area of Mendelian disease gene discovery.

• Prostate Cancer
• Cancer Therapy Resistance
• Molecular Mechanisms
• +7 more

Ping Mu is an Associate Professor with tenure in both the Department of Urology and Department of Pathology at Yale School of Medicine and a member of the Yale Cancer Center. His academic journey began with a BS in Biotechnology from Peking University (2007), followed by a PhD in Biomedical Sciences from Weill Medical College of Cornell University (2013), and postdoctoral training under Dr. Charles L. Sawyers at Memorial Sloan Kettering Cancer Center. In mid-2018, he established his independent laboratory at UT Southwestern as an assistant professor, where his research excellence led to rapid promotion to tenured associate professor before moving to Yale. Dr. Mu's research focuses on uncovering the molecular mechanisms driving resistance to targeted and immune therapies in prostate and other cancers. His lab pursues three exciting research directions: 1) Mechanisms of Therapy Resistance and Tumor Evolution, particularly lineage plasticity, epigenetic rewiring, and mutagenesis; 2) Tumor Microenvironment, Immune Modulation, and Spatial Heterogeneity; and 3) Translational Platforms: AI-Driven Precision Medicine and Patient-Derived Organoids. His work employs state-of-the-art techniques including 3D-cultured organoids, single-cell sequencing, and spatial transcriptomics. Dr. Mu's recent publications show a strong focus on lineage plasticity, epigenetic regulation, and therapy resistance mechanisms in prostate cancer. His high-impact work has been featured in top-tier journals including Science (2017), Cancer Cell (2020, 2023), Cancer Discovery (2024), Nature Cancer (2022), and Nature Genetics (2015), demonstrating a consistent trajectory of significant contributions to the field of cancer research. Selected Scientific Awards: NIH R37 MERIT Award (2021) NIH R01 Research Award (2024) AACR NextGen Stars Award (2020) Prostate Cancer Foundation Young Investigator Award Welch Foundation Research Award Dr. Mu maintains an active research program with multiple NIH and DoD-funded projects. His lab has pioneered important discoveries regarding lineage plasticity mechanisms and novel therapeutic approaches to overcome therapy resistance. The Mu Lab actively collaborates with other researchers at Yale Cancer Center and beyond, contributing to the vibrant research ecosystem at Yale. The lab is particularly known for its work with 3D-cultured organoids and spatial transcriptomics to model therapy resistance in prostate cancer.

• Hair follicle development
• Regeneration
• Dermal niche
• +7 more

Peggy Myung, MD, PhD is Vice Chair of Research and Associate Professor of Dermatology and Pathology at Yale School of Medicine. She maintains strong affiliations across multiple Yale entities including the Yale Cancer Center, Yale Stem Cell Center, Cancer Signaling Networks Program, and Pathology Research Program in Translational Biomedicine. Dr. Myung leads the Myung Lab which focuses on hair follicle development and regeneration research, with applications to understanding skin cancer mechanisms. Dr. Myung received her MD and PhD from the University of Pennsylvania in 2003, completed residencies at Hospital of the University of Pennsylvania and University Hospitals Case Medical Center, and a fellowship at Yale University School of Medicine in 2014. She is board certified in both Dermatology (2012) and Dermatopathology (2014, with recertification in 2025). Her research program investigates how heterotypic signals between the skin epidermis and dermis regulate robust and organized hair follicle growth during embryonic development and adult regeneration. The Myung Lab specifically examines: (1) how cellular behaviors such as cell divisions and movement are regulated by key morphogenetic signals during regeneration, (2) how these signals are spatially disseminated to ensure robust but patterned growth, and (3) how these mechanisms contribute to disorganized growth during tumorigenesis. The hair follicle serves as an ideal model for these studies due to its accessibility and well-characterized cyclical regeneration dependent on resident stem cells. Dr. Myung's recent publication record demonstrates consistent productivity in high-impact journals, with a growing emphasis on single-cell genomic techniques and computational approaches to understand cellular interactions at unprecedented resolution. Her work bridges developmental biology, dermatology, and cancer research, with particular focus on Wnt/β-catenin signaling and epithelial-mmesenchymal interactions. Dr. Myung has received notable recognition including: $30K Biotech Accelerator Award (June 2023) Yale Medicine 'Top Doctor' listing (2024) As Vice Chair of Research, Dr. Myung oversees research initiatives within the Department of Dermatology while maintaining an active laboratory program that combines multi-photon imaging, quantitative RNA fluorescent in situ hybridization, single-cell RNA/ATAC sequencing, and in vivo mouse genetic models. Her long-term goal is to develop novel treatments for hair loss and to prevent and treat non-melanoma skin cancer by applying knowledge of hair morphogenetic signals to suppress aberrant growth in carcinogenesis.

• Epigenetics
• Genome Biology
• Embryonic Development
• +7 more

Zachary Smith is an Assistant Professor (Adjunct) in the Department of Genetics at Yale School of Medicine, with additional affiliations at the Yale Stem Cell Center, Center for RNA Science and Medicine, and the Genomics, Genetics, and Epigenetics program. His research focuses on epigenetic regulation during mammalian development. Dr. Smith received his B.S. in Biology from M.I.T. in 2008 and his Ph.D. in Biology from Harvard University in 2019. His doctoral work focused on applying cutting-edge genomic technologies to understand chromatin dynamics during mammalian development. He joined the Yale Stem Cell Center and Department of Genetics as an Assistant Professor in September 2020. Dr. Smith's research program investigates three critical developmental processes: fertilization, implantation, and gastrulation. His lab seeks to understand how the genome is reconstructed after fertilization, how distinct epigenetic states are established in embryonic versus extraembryonic lineages, and how chromatin regulators orchestrate the complex process of gastrulation. They employ advanced genomic techniques including single-cell sequencing, Cas9-mediated genome editing, and novel molecular recording technologies. His recent publications highlight significant contributions to understanding DNA methylation dynamics in development and disease, X-chromosome biology, and the development of innovative genomic technologies. Dr. Smith's work bridges fundamental developmental biology with potential applications to understanding developmental disorders and cancer. Epigenetic regulation of mammalian development Chromatin dynamics during embryogenesis DNA methylation reprogramming Single-cell genomic analysis Novel molecular recording technologies Dr. Smith's lab collaborates extensively with researchers at Yale and other institutions, including Michael Caplan, Berna Sozen, and Biff Forbush. His interdisciplinary approach combines expertise in genetics, developmental biology, and technology development to address fundamental questions about how epigenetic mechanisms shape development. Students and postdocs in Dr. Smith's lab have opportunities to work at the forefront of developmental epigenetics, gaining expertise in both experimental and computational approaches to studying genome regulation during development.

• RNA Biology
• Computational Biology
• Hematologic Neoplasms
• +5 more

Toma Tebaldi is an Assistant Professor Adjunct in the Medical Oncology and Hematology department at Yale School of Medicine and a member of the Yale Cancer Center. His interdisciplinary work bridges computational biology and cancer research, with a focus on RNA mechanisms in hematologic malignancies. Dr. Tebaldi maintains affiliations with multiple research programs including Genomics, Genetics, and Epigenetics, and Internal Medicine at Yale. Dr. Tebaldi's educational background includes a PhD in Information and Communication Technology from the University of Trento (2010), an MSc in Biotechnologies - Bioinformatics from University of Milano Bicocca (2006), and a BSc in Biotechnologies from the same institution (2003). His training includes postdoctoral fellowships at University of Trento, EMBO Short Fellowship at University of Edinburgh, and international internships at Harvard Medical School, University of Edinburgh, and University of Sheffield. His research focuses on RNA molecular mechanisms underlying disease dysregulation, combining experimental and computational approaches. Key areas include alternative splicing, non-coding RNA binding, mutant RNA binding proteins, RNA modifications (epitranscriptome), translation dynamics, and single-cell expression data. This work has significant implications for understanding and treating hematologic cancers. Dr. Tebaldi's publication record shows consistent output in high-impact journals from 2022-2025, with research spanning cancer biology, RNA mechanisms, and computational approaches. His work demonstrates increasing sophistication in integrating single-cell technologies with traditional molecular biology techniques to address complex questions in cancer biology. Italian National Scientific Qualification as Associate Professor in Applied Biology (2021) Italian National Scientific Qualification as Associate Professor in Molecular Biology (2020) Yale YCCEH Pilot and Feasibility Program Award (2018) RNA Society Travel Award: RNA2016, Kyoto (2016) EMBO Travel Grant Award: Protein synthesis and translational control (2015) Dr. Tebaldi serves as Associate Editor for Frontiers in Genetics - Computational Biology and as a reviewer for PRIN 2020 MIUR. His membership in the Yale Center for Biomedical Data Science and Yale Cancer Center provides access to extensive collaborative networks and resources. His research program benefits from interdisciplinary connections between computational biology, cancer genomics, and clinical hematology/oncology. Through his Italian Society of Yale Students and Affiliates board membership and Visiting Professor appointments at University of Trento, Dr. Tebaldi maintains strong international connections that enrich his research program and provide opportunities for student exchanges and collaborative projects across continents.

• Autoimmunity
• Dermatology
• Immunology
• +4 more

Mary Tomayko, MD, PhD is an Associate Professor of Dermatology and Pathology at Yale University School of Medicine. She serves as Director of the Yale Immunobullous Clinic and Director of Dermatology Medical Student Education. Dr. Tomayko is actively involved in clinical care at Yale Medicine Dermatology, Yale Health, and Yale New Haven Hospital. Her research focuses on understanding immune dysregulation in bullous pemphigoid and mechanisms of long-lasting immunity. The Tomayko Lab has made significant contributions to understanding memory B cell biology, identifying novel pathways essential for immune memory. Her NIH-funded research bridges basic science with clinical applications for autoimmune skin diseases. Dr. Tomayko's clinical expertise encompasses complex autoimmune and inflammatory skin disorders including pemphigus, pemphigoid, epidermolysis bullosa acquisita, atopic dermatitis, vitiligo, alopecia areata, and psoriasis. She employs a comprehensive treatment approach using systemic immunomodulators, biologic agents, traditional immunosuppressants, and phototherapy. Her recent publications (2023-2025) demonstrate active research in autoimmune blistering diseases, with significant work on the psychosocial burden of these conditions, immune checkpoint inhibitor-related dermatological complications, and translational immunology research. Her collaborative work spans multiple disciplines including oncology, immunology, and medical education. Yale Medicine Top Doctor 2023 Yale Medicine Top Doctor 2024 Dr. Tomayko actively mentors students at all levels and contributes to dermatology education at Yale. Her dual MD/PhD training provides a unique foundation for translational research that directly informs her clinical practice in immunodermatology.

• Cancer genetics
• Somatic evolution of cancer
• Biostatistics
• +5 more

Jeffrey Townsend is the Elihu Professor of Biostatistics and Professor of Ecology and Evolutionary Biology at Yale University. He serves as Co-Director of the Genetics, Genomics, and Epigenetics Program of the Yale Cancer Center and Co-Chair of the Cancer Evolution Working Group of the American Association for Cancer Research. His academic journey began with a Biology degree from Brown University (1994), followed by a PhD in Organismic & Evolutionary Biology from Harvard University (2002), and a Miller Fellowship at UC Berkeley (2004). Professor Townsend's research spans two primary areas: cancer genetics/epidemiology and biostatistical modeling of disease spread. His lab develops algorithmic approaches to identify cancer-causing mutations by applying evolutionary theory to somatic mutation patterns. In epidemiology, he pioneers probabilistic methods for modeling disease transmission that account for parameter uncertainty, providing more robust public health guidance. His work bridges evolutionary biology, biostatistics, and medical research with significant implications for personalized cancer treatments and infectious disease control strategies. His research interests encompass cancer evolution, genomic analysis, infectious disease modeling, and evolutionary biology applications to medicine. Townsend's publications reveal a strong focus on mutation patterns in lung cancer, viral evolution, and mathematical approaches to understanding disease dynamics. His recent work includes analyses of KRAS mutations in NSCLC, the evolution of SARS-CoV-2 immunity, and precision projections for delaying resistance mutations in cancer therapy. Reducing Disease Risk Research Award (2023, Yale School of Public Health) Translational Research Prize (2016, Yale Cancer Center) Young Investigator's Prize (2005, American Society of Naturalists) Top Four Life Science Theses (2002, Council of Graduate Schools) Walter M. Fitch Prize for Best Young Investigator (2001) Professor Townsend advises graduate students and postdoctoral researchers in the Townsend Lab, where they work at the intersection of evolutionary biology, biostatistics, and medical research. His lab maintains active collaborations with Yale's Cancer Center, School of Public Health, and numerous co-authors including Francesc Lopez-Giraldez, Zheng Wang, and Alison Galvani. Current projects focus on cancer evolution mechanisms, optimal timing for vaccine boosters, and mathematical models that incorporate uncertainty for public health decision-making. The Townsend Lab operates at 60 College Street, 7th Floor in New Haven, Connecticut, with close connections to Yale's Cancer Center and School of Public Health. The lab's research has practical applications in developing personalized cancer treatments and informing public health policy for infectious disease control, demonstrating the translational impact of Townsend's interdisciplinary approach to biomedical research.

Roel VerhaakView profile

Professor

• Brain Tumor Research
• Glioma Evolution
• Extrachromosomal DNA Amplification
• +5 more

Roel Verhaak, PhD, is a Professor in the Department of Neurosurgery at the Yale School of Medicine, holding the prestigious Harvey and Kate Cushing Professorship. He maintains extensive affiliations across Yale's research ecosystem, including the Genomics, Genetics, and Epigenetics Program, Human Genome Sciences, Molecular Medicine, Pharmacology, and Physiology, the Neurosurgery Program in Translational Biomedicine, and the Yale Cancer Center. Dr. Verhaak earned his PhD from Erasmus University Medical Center in Rotterdam, followed by postdoctoral training at the Broad Institute/Dana-Farber Cancer Institute. He established his independent research program at MD Anderson Cancer Center in 2010, was affiliated with the Jackson Laboratory for Genomic Medicine from 2016, and joined Yale School of Medicine in 2023. His research focuses on brain tumors and extrachromosomal DNA amplification in cancer. The Verhaak Lab studies tumor evolution and therapy resistance mechanisms in gliomas using high-throughput sequencing, computational analysis, and functional studies. He leads the Glioma Longitudinal Analysis Consortium (GLASS) and made the groundbreaking discovery that extrachromosomal DNA amplifications are critical cancer drivers. Dr. Verhaak's publication record shows a consistent focus on advancing our understanding of glioma biology and cancer genomics, with recent work (2023-2025) emphasizing extrachromosomal DNA mechanisms, glioma evolution, and novel therapeutic approaches. His research has shifted from initial molecular classification work to deeper mechanistic understanding of tumor evolution and resistance. AAAS Martin and Rose Wachtel Cancer Research Award (2016) Adult Basic Science Award from the Society for Neuro-Oncology (2014) Peter Steck Memorial Award from the Pediatric Brain Tumor Foundation (2012) Wilson S. Stone Memorial Award from MD Anderson Cancer Center (2011) Dr. Verhaak actively mentors researchers and collaborates extensively across institutions. He co-founded Boundless Bio to translate his discoveries about extrachromosomal DNA into therapeutic approaches. His lab participates in major consortia including the GBM Cellular Analysis of Resistance and Evolution (CARE) consortium, which has refined our understanding of glioblastoma's cellular architecture through single-cell transcriptomics. The Verhaak Lab maintains a strong research presence with multiple active projects focused on understanding how extrachromosomal DNA drives cancer progression and developing strategies to target this mechanism therapeutically.

• Hematopathology
• Oncologic Biomarkers
• Leukemia
• +5 more

Dr. Mina Xu is a Professor of Pathology and Laboratory Medicine at Yale School of Medicine, specializing in hematopathology and oncologic diagnostics. She directs Yale's Hematopathology division and Expert Consultation Practice, with affiliations spanning the Yale Cancer Center's genomics and immuno-oncology programs. Her research targets hematopoietic malignancies (leukemia, lymphoma, myeloma), biomarker discovery, and molecular diagnostics, utilizing cutting-edge techniques like spatial transcriptomics and AI-driven histopathology. Research Focus: Dr. Xu's work bridges tumor immunology, diagnostic innovation, and translational medicine. Key interests include: Development of immunohistochemical biomarkers for myeloid/lymphoid neoplasms Machine learning applications in predicting lymphoma transformation Spatial multi-omics mapping in archival tissue samples Therapeutic response prediction in targeted cancer therapies Recent Publications: Her 118+ articles (2023-2025) in journals like Nature Biotechnology and Blood demonstrate focus on: (1) Spatial transcriptomics for tumor microenvironments, (2) AI-enhanced diagnostic criteria, and (3) Novel biomarkers for hematologic malignancies. Trends show increasing integration of computational biology with clinical pathology. Awards & Honors: American Society of Hematology Trainee Grant (2005) Westinghouse Science Award (1996) National Science Foundation Trainee Grant (1994) Weizmann Institute of Science Scholarship (1996) Training & Collaboration: Actively mentors residents/fellows in pathology and collaborates with 13+ principal investigators, including Dr. Stephanie Halene (12 joint publications) and Dr. Amer Zeidan (9 joint publications). Research emphasizes team science within Yale Cancer Center consortia.

• Computational Biology
• Bioinformatics
• Neurogenomics
• +4 more

Lukas Steuernagel leads the Neurogenomics Research Group at the Max Planck Institute for Metabolism Research in Cologne, Germany. His laboratory focuses on developing and applying computational biology methods to understand the brain's role in regulating metabolism and energy balance. His research program explores the full spectrum of neuronal cell types in the hypothalamus and hindbrain, moving beyond established models of Agrp and Pomc neurons. The group studies neurons at transcriptomic, epigenomic, metabolomic, and spatial levels to understand how genetic and environmental factors influence metabolism-regulating cell types. Dr. Steuernagel's recent publications demonstrate expertise in creating comprehensive cellular maps of the hypothalamus, with work appearing in top-tier journals including Nature and Nature Metabolism. His research addresses three main areas: mapping cell type architecture of metabolic brain regions, effects of genetics and environment on metabolism-regulating cells, and interpretation of large-scale OMICS data. He maintains active collaborations with other research groups at the institute to translate computational findings into biological mechanisms.

Korbinian SchneebergerView profile

Research Professor

• Genomic Biotechnology
• Plant Genomics
• Computational Genetics
• +4 more

Prof. Dr. Korbinian Schneeberger is a Research Professor and Group Leader at the Department of Plant Developmental Biology, Max Planck Institute for Plant Breeding Research in Cologne, Germany. His research focuses on genome plasticity and computational genetics, developing cutting-edge technologies to explore genome evolution. He leads a multidisciplinary team consisting of bioinformaticians, biologists, and biotechnologists driven by curiosity and passion for new genomic technologies. Dr. Schneeberger's research group pioneers genomic biotechnology for crop biology, addressing real-world problems in genomics-assisted science and breeding using Arabidopsis, potato, and fruit trees as model systems. They study genomic differences, how to find and describe them, and their relevance to phenotype. The group specializes in single-cell sequencing technologies to understand controlled (recombination) and uncontrolled (mutations) events that drive genomic diversity. His research spans four main areas: Optimizing Plant Performance by Mapping the Interface between Development and Metabolism, Plant Microbiota Metabolic Networks and Edaphic Adaptation, Synthetic and Reconstruction Biology, and Theoretical Plant Biology and Data Science. The group has developed several important bioinformatics tools including SyRI for finding genomic rearrangements, plotsr for visualization, SHOREmap for mapping-by-sequencing, and findGSE for genome size estimation. Genome Assembly: Developing new methods for genome assembly, particularly using long-read sequencing data Genomic Variation: Studying mutation accumulation and its role in evolution and adaptation Computational Genetics: Bridging genotype and phenotype using next-generation sequencing Association Studies: Creating methods that associate morphological differences to genomic differences Dr. Schneeberger's recent publications focus on somatic mutations in fruit trees, pan-genome analysis of Arabidopsis, and chromosome-scale genome assembly of potato. His work has significant implications for understanding plant evolution and improving crop breeding strategies. He mentors several PhD students and postdocs, with alumni who have gone on to successful careers in academia and industry. His laboratory maintains the Plant Metabolism and Metabolomics Facility and an Imaging Platform.

Franziska TurckView profile

Professor

• Epigenetics
• Plant Development
• Chromatin Structure
• +5 more

Dr. Franziska Turck is a Professor and Research Group Leader in the Department of Plant Developmental Biology at the Max Planck Institute for Plant Breeding Research in Cologne, Germany. Her laboratory focuses on epigenetic mechanisms that regulate plant development, particularly how plants form transcriptional memories based on past experiences through chromatin modifications. Dr. Turck's research centers on epigenetic pathways, particularly Polycomb Group (PcG) protein complexes that establish chromatin compaction leading to gene repression. Her group investigates mechanisms that recruit and stabilize epigenetic repression and how distal enhancers can overcome epigenetic gene repression. Key projects include studying Polycomb Group Proteins in Plant Development and the Regulation of FLOWERING LOCUS T by distal enhancers and epigenetic repressors. Her work has revealed how TELOMERE REPEAT BINDING FACTORs recruit Polycomb Repressive Complex 2 to target regions and how chromatin accessibility at the FLOWERING LOCUS T locus is regulated by distal enhancers within PcG-repressed chromatin. Analysis of Dr. Turck's recent publications shows a consistent focus on plant epigenetics, chromatin structure, and flowering time regulation. Her work bridges molecular mechanisms with developmental outcomes, particularly in how plants integrate environmental cues through epigenetic memory systems. Many publications appear in high-impact journals including Nature Genetics, Nature Plants, and PNAS, with several receiving Faculty of 1000 recommendations. Faculty of 1000 Recommendation for Targeted DNA methylation represses two enhancers of FLOWERING LOCUS T in Arabidopsis thaliana (2019) Faculty of 1000 Recommendation for Telobox motifs recruit CLF/SWN–PRC2 for H3K27me3 deposition via TRB factors in Arabidopsis (2018) Faculty of 1000 Recommendation for H2A monoubiquitination in Arabidopsis thaliana is generally independent of LHP1 and PRC2 activity (2017) Dr. Turck mentors several PhD students including Juanjuan Wang (recently defended), Nicole Ivanov, Maik Mendler, Prathamesh Sannak, and Haoran Zhou. Her lab consists of postdocs, PhD students, and technical staff working on various aspects of plant epigenetics. Current projects include investigating TRB proteins' role in coordinating expression of translational machinery genes and floral organ identity genes, and exploring induced gametophytic embryogenesis through single-cell transcriptomics and epigenomics (EpiHAP project). The Turck lab maintains active collaborations and participates in multiple research initiatives focused on understanding how epigenetic mechanisms control plant development and adaptation. The group utilizes advanced genomic, molecular, and imaging techniques to investigate chromatin dynamics at both whole-genome and locus-specific levels.

• Neuroimmunology
• Neurodegenerative Diseases
• Single-cell Omics
• +4 more

Marc Beyer serves as Group Leader at the German Center for Neurodegenerative Diseases (DZNE) in Bonn, holding the academic rank of Associate Professor. His research investigates bidirectional immune-brain interactions during aging and neurodegeneration, with emphasis on T cell and microglial mechanisms in Alzheimer's, Parkinson's, and post-COVID neurological complications. Dr. Beyer's group pioneers single-cell multi-omic approaches including snRNA-seq, scATAC-seq, and spatial transcriptomics to decode cellular heterogeneity in neurodegenerative contexts. Key projects involve creating human brain cell atlases (DFG-NGS collaboration), characterizing dopaminergic neuron transcriptional changes in Parkinson's, and exploring 'innate immune memory' in microglia. The NeuroCOV initiative identifies peripheral blood immune signatures linked to long-term cognitive decline after SARS-CoV-2 infection. Scientific Awards: No awards specified in source materials. Dr. Beyer directs multiple high-impact projects including a large DZNE cohort study on peripheral immunity in early dementia and the European NeuroCOV consortium. These initiatives employ high-throughput single-cell analysis of PBMCs to develop biomarkers for early therapeutic intervention, though specific grant details and student mentorship records remain unlisted. The research team operates from DZNE's Venusberg Campus facility, utilizing CRISPR-Cas9 lineage tracing (LINC mouse model), high-dimensional flow cytometry, and multimodal omics platforms to dissect neuroimmune crosstalk in physiological and pathological CNS states.

• Neurodegenerative diseases
• Alzheimer's disease
• Microglia
• +5 more

Prof. Dr. Jonas Neher serves as a Group Leader at the German Center for Neurodegenerative Diseases (DZNE) in Munich, where he leads research focused on the role of microglia and immune responses in neurodegenerative diseases, particularly Alzheimer's disease. His laboratory investigates how peripheral inflammation affects brain pathology through mechanisms like innate immune memory and epigenetic reprogramming. Dr. Neher's research program centers on understanding how microglia contribute to Alzheimer's pathology, particularly amyloidosis and neuronal damage. He has demonstrated that microglia are capable of 'remembering' inflammatory insults through epigenetic reprogramming, creating long-term adaptations that significantly affect brain disease progression. His work has established innate immune memory as a previously unrecognized non-genetic risk factor for neurodegenerative diseases. Additionally, he studies vascular dysfunction in Alzheimer's disease, with a particular focus on medin amyloid, which is now recognized as a common factor in age-related arterial stiffening and a potential therapeutic target for millions affected by cognitive decline. Analysis of Dr. Neher's publication record reveals a strong trajectory from fundamental immunological mechanisms to translational applications. His recent work (2022-2024) shows increasing focus on medin amyloid's role in vascular pathology, with high-impact publications in Nature and Nature Aging. His laboratory has developed specialized single-cell profiling techniques that combine transcriptomic and epigenetic analyses to better understand cellular heterogeneity in neurodegenerative conditions. This methodological innovation enables more precise characterization of microglial subtypes and their responses to inflammatory stimuli. Dr. Neher leads an active research group investigating how peripheral inflammatory stimuli affect the brain's immune response and contribute to neurodegenerative disease pathology. His laboratory has developed specialized methods for profiling microglia and other brain cells at the single-cell level, combining transcriptomic and epigenetic analyses to better understand cellular heterogeneity in health and disease. His research bridges basic science with potential clinical applications, particularly in developing new therapeutic strategies targeting both immune and vascular components of Alzheimer's disease.

• Systems Immunology
• Genomics
• Artificial Intelligence
• +4 more

Prof. Dr. Joachim L. Schultze is Director of Systems Medicine at the German Center for Neurodegenerative Diseases (DZNE) and leads the Genomics & Immunoregulation group at the University of Bonn's LIMES Institute. His research integrates immunology, neurobiology, genomics, and artificial intelligence, with a focus on single-cell technologies and systems medicine approaches. Key research areas include: Swarm Learning : Development of decentralized AI frameworks for medical research NEUROCOV : Investigation of neurological complications in COVID-19 PRECISE Platform : Single-cell genomics and epigenomics technology development Systems immunology approaches for chronic inflammatory diseases Myeloid cell biology and trained immunity mechanisms His recent publications (2019-2022) demonstrate strong focus on: COVID-19 immunopathology and myeloid cell dysregulation Neuroimmunology and neurodegenerative disorders AI/blockchain applications in healthcare Single-cell transcriptomics in inflammation Metabolic regulation of immune cells Prof. Schultze coordinates multiple international consortia including the DFG-funded NGS Competence Network and Immunosensation2 Cluster of Excellence. His laboratory combines experimental genomics with computational biology at the PRECISE joint platform between DZNE and University of Bonn.